1,2-二氢-2-氧代-6-(三氟甲基)-3-吡啶基-N-苯甲酰胺 | 74877-62-6

• 分子结构分类: 有机化合物 - 有机酸及其衍生物 - 羧酸及其衍生物
• 中文名称: 1,2-二氢-2-氧代-6-(三氟甲基)-3-吡啶基-N-苯甲酰胺
• 英文名称: ethyl N-(3-hydroxypropyl) carbamate
• 英文别名: ethyl 3-hydroxypropylcarbamate；Carbamic acid, (3-hydroxypropyl)-, ethyl ester；ethyl N-(3-hydroxypropyl)carbamate
• CAS: 74877-62-6
• 化学式: C₆H₁₃NO₃
• 分子量: 147.174
• InChiKey: PUMHTFXHONFKOH-UHFFFAOYSA-N

物化性质

• 沸点：
  140-142 °C(Press: 5 Torr)
• 密度：
  1.071±0.06 g/cm3(Predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  0
• 重原子数：
  10
• 可旋转键数：
  5
• 环数：
  0.0
• sp3杂化的碳原子比例：
  0.83
• 拓扑面积：
  58.6
• 氢给体数：
  2
• 氢受体数：
  3

反应信息

• 作为反应物：
  描述：

  1,2-二氢-2-氧代-6-(三氟甲基)-3-吡啶基-N-苯甲酰胺 在 硝酸乙酸酐 作用下， 反应 0.33h， 以67%的产率得到ethyl N-(3-hydroxypropyl)-nitrocarbamate nitrate
  参考文献：
  名称：

  五氧化二氮（N 2 O 5）通过氮杂环丁烷的开环硝化反应制得硝酸硝胺

  摘要：

  在低于室温的温度下，在氯化溶剂中用N 2 O 5处理11个在环氮上带有各种取代基的氮杂环丁烷，在某些情况下，通过类似的新型开环硝化反应，形成1，3-硝胺-硝酸盐产物。到建立氮丙啶的水平。发生开环的硝酸硝胺硝酸盐的收率通常为中到高（41–88％），但带有N-酰基取代基（乙酰基，丁酰基或氨基甲酰基）的氮杂环丁烷则进行环外取代基的硝化反应以形成N -硝基氮杂环丁烷。同样，带有强吸电子基团（如苦味酚）的氮杂环丁烷对N 2 O 5呈惰性。与氮丙啶相比，氮杂环丁烷的不同反应性是根据四元环化合物的降低的环应变来合理化的。

  DOI：

  10.1016/0040-4020(95)98704-l
• 作为产物：
  描述：

  ethyl α-methoxyvinyl carbonate 、 3-氨基-1-丙醇 以 二氯甲烷 为溶剂， 反应 0.08h， 以71%的产率得到1,2-二氢-2-氧代-6-(三氟甲基)-3-吡啶基-N-苯甲酰胺
  参考文献：
  名称：

  Facile and efficient carboalkoxylation and carboaryloxylation of amines

  摘要：

  DOI：

  10.1021/jo01310a057

文献信息

• [EN] NOVEL COMPOUNDS<br/>[FR] NOUVEAUX COMPOSÉS
  申请人：INFLAZOME LTD

  公开号：WO2019068772A1

  公开（公告）日：2019-04-11

  The present invention relates to compounds of formula (I): wherein Q is selected from O or S; R1 is a saturated or unsaturated hydrocarbyl group, wherein the hydrocarbyl group may be straight-chained or branched, or be or include cyclic groups, wherein the hydrocarbyl group may optionally be substituted, and wherein the hydrocarbyl group may optionally include one or more heteroatoms N, O or S in its carbon skeleton; and R2 is a cyclic group substituted at the a-position, wherein R2 may optionally be further substituted. The present invention further relates to salts, solvates and prodrugs of such compounds, to pharmaceutical compositions comprising such compounds, and to the use of such compounds in the treatment and prevention of medical disorders and diseases, most especially by the inhibition of NLRP3.

  本发明涉及以下式(I)的化合物：其中Q从O或S中选择；R1是饱和或不饱和的烃基团，其中烃基团可以是直链或支链的，或者包括环状基团，其中烃基团可以选择性地被取代，并且其中烃基团的碳骨架中可以选择性地包含一个或多个杂原子N、O或S；以及R2是在α位取代的环状基团，其中R2可以选择性地进一步取代。本发明还涉及这些化合物的盐、溶剂合物和前药，包括这些化合物的药物组合物，以及利用这些化合物治疗和预防医学疾病和疾病的用途，尤其是通过抑制NLRP3。
• The Biological Effects of Structural Variation at the Meta Position of the Aromatic Rings and at the End of the Alkenyl Chain in the Alkenyldiarylmethane Series of Non-Nucleoside Reverse Transcriptase Inhibitors
  作者：Guozhang Xu、Mark Micklatcher、Maximilian A. Silvestri、Tracy L. Hartman、Jennifer Burrier、Mark C. Osterling、Heather Wargo、Jim A. Turpin、Robert W. Buckheit,、Mark Cushman

  DOI：10.1021/jm010212m

  日期：2001.11.1

  In an effort to elucidate a set of structure-activity relationships in the alkenyldiarylmethane (ADAM) series of non-nucleoside reverse transcriptase inhibitors, a number of modifications were made at two locations: (1) the meta positions of the two aromatic rings and (2) the end of the alkenyl chain. Forty-two new ADAMs were synthesized and evaluated for inhibition of the cytopathic effect of HIV-1(RF)

  为了阐明在烯基二芳基甲烷（ADAM）系列非核苷类逆转录酶抑制剂中的一系列结构活性关系，在两个位置进行了许多修饰：（1）两个芳环的间位和（ 2）烯基链的末端。合成了42种新的ADAM，并评估了它们在CEM-SS细胞培养中对HIV-1（RF）的细胞病变作用的抑制作用以及对HIV-1逆转录酶的抑制作用。发现芳族取代基的大小会影响抗HIV活性，Cl，CH（3）和Br取代基具有最佳活性，而较小（H和F）或较大（I和CF（3）则具有减弱的活性。 ））取代基。还发现烯基链末端的取代基会影响抗病毒活性，具有与甲基或乙基酯基团相关的最大活性，并且由于被高级酯，酰胺，硫化物，亚砜，砜，砜，酯，缩醛，酮，氨基甲酸酯，脲和硫脲取代而导致的活性降低。十二个新的ADAM显示出亚微摩尔EC（50）值，可抑制CEM-SS细胞中HIV-1（RF）的细胞病变作用。将选定的ADAM 19和21与先前发布的ADAM 15和17的
• NOVEL AZALIDE AND AZALACTAM DERIVATIVES AND PROCESS FOR THE PRODUCTION OF THE SAME
  申请人：Meiji Seika Kaisha, Ltd.

  公开号：EP1661904A1

  公开（公告）日：2006-05-31

  A compound represented by the following general formula (1) or a pharmaceutically acceptable salt thereof, which is useful for a prophylactic and/or therapeutic treatment of a microbial infectious disease. [R1 is hydrogen atom, or a linear C1-6 alkylcarbonyl group; R2 is hydrogen atom, or a C1-6 alkylcarbonyl group; R3 is hydrogen atom, a C1-6 alkyl group, a C1-6 alkylcarbonyl group, a C1-6 alkenyl group, a C2-6 alkenylcarbonyl group, a C2-6 alkynyl group, or an Ar-B- group (Ar represents an aryl group, or a heterocyclic group, and B is a C1-6 alkyl group, a C1-6 alkylcarbonyl group, a C2-6 alkenyl group, a C2-6 alkenylcarbonyl group, or a C2-6 alkynyl group); R5, R6, R7, and R8 represent hydrogen atom, a C1-6 alkyl group, a C2-6 alkenyl group, a C2-6 alkynyl group, or an Ar-B'- group (B' is a C1-6 alkyl group, a C2-6 alkenyl group, or a C2-6 alkynyl group); X is oxygen atom, or an -NR4- group (R4 is hydrogen atom, a C1-6 alkyl group, or a C1-6 alkyl group which may be substituted with an Ar group); and R4' is hydrogen atom, or a group represented by the aforementioned formula (a) (R3" and R4" represent hydrogen atom, or a linear or branched C1-6 alkylcarbonyl group)]

  由以下一般式（1）表示的化合物或其药学上可接受的盐，可用于预防和/或治疗微生物感染性疾病。[R1为氢原子，或线性C1-6烷基羰基基团；R2为氢原子，或C1-6烷基羰基基团；R3为氢原子，C1-6烷基基团，C1-6烷基羰基基团，C1-6烯基基团，C2-6烯基羰基基团，C2-6炔基基团，或Ar-B-基团（Ar表示芳基团，或杂环基团，B为C1-6烷基基团，C1-6烷基羰基基团，C2-6烯基基团，C2-6烯基羰基基团，或C2-6炔基基团）；R5、R6、R7和R8表示氢原子，C1-6烷基基团，C2-6烯基基团，C2-6炔基基团，或Ar-B'-基团（B'为C1-6烷基基团，C2-6烯基基团，或C2-6炔基基团）；X为氧原子，或一个-NR4-基团（R4为氢原子，C1-6烷基基团，或C1-6烷基基团，可能被芳基取代）；R4'为氢原子，或由上述式（a）表示的基团（R3"和R4"表示氢原子，或线性或支链状C1-6烷基羰基基团）]
• Efficient synthesis of 3-methylene-2-pyrrolidinone and highly exoselective Diels-Alder addition to cyclopentadiene
  作者：Frédéric Fotiadu、Olivier Pardigon、Gérard Buono、Maurice Le Corre、Alain Hercouët

  DOI：10.1016/s0040-4039(98)02542-8

  日期：1999.1

  3-methylene 2-pyrrolidinone 1 ylide-lactame 6 is reported. Diels-Alder cycloadditions of 1 to cyclopentadiene exhibited very high exoselectivities, regardless of the experimental conditions. These results confirm the generality of exoselectivity for conformationally restricted s-cis dienophiles and indicate that the dienophile functionality and dipole moment have little influence on its magnitude.

  报道了3-亚甲基2-吡咯烷酮1内酯-内酰胺6的新的有效合成。不管实验条件如何，Diels-Alder 1与环戊二烯的环加成反应都具有很高的放出选择性。这些结果证实了构象受限的s-顺式亲二烯体的选择性的一般性，并且表明亲二烯体的功能性和偶极矩对其幅度的影响很小。
• Nozel azalide and azalactam derivatives and method for producing the same
  申请人：Miura Tomoaki

  公开号：US20070042974A1

  公开（公告）日：2007-02-22

  A compound represented by the following general formula (1) or a pharmaceutically acceptable salt thereof, which is useful for a prophylactic and/or therapeutic treatment of a microbial infectious disease. [R 1 is hydrogen atom, or a linear C1-6 alkylcarbonyl group; R 2 is hydrogen atom, or a C1-6 alkylcarbonyl group; R 3 is hydrogen atom, a C1-6 alkyl group, a C1-6 alkylcarbonyl group, a C1-6 alkenyl group, a C2-6 alkenylcarbonyl group, a C2-6 alkynyl group, or an Ar—B— group (Ar represents an aryl group, or a heterocyclic group, and B is a C1-6 alkyl group, a C1-6 alkylcarbonyl group, a C2-6 alkenyl group, a C2-6 alkenylcarbonyl group, or a C2-6 alkynyl group); R 5 , R 6 , R 7 , and R 8 represent hydrogen atom, a C1-6 alkyl group, a C2-6 alkenyl group, a C2-6 alkynyl group, or an Ar—B′— group (B′ is a C1-6 alkyl group, a C2-6 alkenyl group, or a C2-6 alkynyl group); X is oxygen atom, or an —NR 4 — group (R 4 is hydrogen atom, a C1-6 alkyl group, or a C1-6 alkyl group which may be substituted with an Ar group); and R 4′ is hydrogen atom, or a group represented by the aforementioned formula (a) (R 3″ and R 4″ represent hydrogen atom, or a linear or branched C1-6 alkylcarbonyl group)]

  下列通式（1）所代表的化合物或其药学上可接受的盐，可用于预防和/或治疗微生物感染性疾病。[其中R1为氢原子或线性C1-6烷基羰基基团；R2为氢原子或C1-6烷基羰基基团；R3为氢原子、C1-6烷基、C1-6烷基羰基基团、C1-6烯基、C2-6烯基羰基基团、C2-6炔基或Ar-B-基团（Ar代表芳基或杂环基，B为C1-6烷基、C1-6烷基羰基基团、C2-6烯基、C2-6烯基羰基基团或C2-6炔基）；R5、R6、R7和R8代表氢原子、C1-6烷基、C2-6烯基、C2-6炔基或Ar-B′-基团（B′为C1-6烷基、C2-6烯基或C2-6炔基）；X为氧原子或-NR4-基团（R4为氢原子、C1-6烷基或可被芳基取代的C1-6烷基）；R4′为氢原子或上述通式（a）所代表的基团（R3″和R4″代表氢原子或线性或支链状C1-6烷基羰基基团）]